Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | SF3B1-mutant MDS: a new disease subtype

David Sallman • 28 May 2020
ASCO 2020
Myelodysplastic Syndromes Luspatercept
MEDALIST

David Sallman, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, discusses the recognition of a distinct subtype of myelodysplastic syndrome (MDS) based on the presence of a genetic mutation known as SF3B1. Dr Sallman reveals that patients with MDS who carry this genetic variant have a relatively good prognosis. Additionally, a recent clinical trial (MEDALIST; NCT02631070) showed that a high proportion of patients who carried the SF3B1 mutation responded to treatment with luspatercept. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from David Sallman

2:08
Hematological response to frontline treatment in LR-MDS is associated with better OS
David Sallman • 9 Dec 2023
1:58
Canakinumab plus darbepoetin in patients with LR-MDS following ESA failure
David Sallman • 9 Dec 2023
2:49
Front-line treatment options for HR-MDS: can we move past azacitidine?
David Sallman • 9 Dec 2023
Transplantation & immunotherapies
Charles Craddock et al. • 4 Sep 2023

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals